Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Powles Thomas; Duran Ignacio; van der Heijden Michiel S.; Loriot Yohann; Vogelzang Nicholas J.; De Giorgi Ugo; Oudard Stephane; Retz Margitta M.; Castellano Daniel; Bamias Aristotelis; Flechon Aude; Gravis Gwenaelle; Hussain Syed; Takano Toshimi; Leng Ning; Kadel Edward E. III; Banchereau Romain; Hegde Priti S.; Mariathasan Sanjeev; Cui Na; Shen Xiaodong; Derleth Christina L.; Green Marjorie C.; Ravaud Alain

首页> 外文期刊>The Lancet >Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

【24h】

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

机译：紫红素与化疗铂治疗的局部晚期或转移性尿路上皮癌（IMVigor211）：多期，开放标签，第3期随机对照试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population.

机译：背景技术存在临床或转移性尿路上皮癌的患者的少数选择，铂基化学疗法进展后。我们旨在评估atezolizumab（反编程死亡 - 配体1 [PD-L1]）与化疗的安全性和有效性在该患者群体中。

著录项

来源
《The Lancet》 |2018年第10122期|共10页
作者
Powles Thomas; Duran Ignacio; van der Heijden Michiel S.; Loriot Yohann; Vogelzang Nicholas J.; De Giorgi Ugo; Oudard Stephane; Retz Margitta M.; Castellano Daniel; Bamias Aristotelis; Flechon Aude; Gravis Gwenaelle; Hussain Syed; Takano Toshimi; Leng Ning; Kadel Edward E. III; Banchereau Romain; Hegde Priti S.; Mariathasan Sanjeev; Cui Na; Shen Xiaodong; Derleth Christina L.; Green Marjorie C.; Ravaud Alain;
展开▼
作者单位

Queen Mary Univ London Barts Canc Inst St Bartholomews Hosp Expt Canc Med Ctr London E1 4NS;

Univ Seville CSIC Hosp Univ Virgen del Rocio Inst Biomed Seville IBiS Seville Spain;

Netherlands Canc Inst Dept Med Oncol Amsterdam Netherlands;

Univ Paris Saclay Dept Med Oncol Gustave Roussy Villejuif France;

US Oncol Res Comprehens Canc Ctr Nevada Las Vegas NV USA;

Ist Sci Romagnolo Studio &

Cura Tumori IRST IRCCS Meldola Italy;

Rene Descartes Univ European Georges Pompidou Hosp Oncol Dept Paris France;

Tech Univ Munich Dept Urol Klinikum Rechts Isar Munich Germany;

Univ Hosp 12 Octubre Med Oncol Dept CIBER ONC Madrid Spain;

Univ Athens Alexandra Hosp Athens Greece;

Ctr Leon Berard Lyon France;

Inst Paoli Calmette Dept Canc Med Marseille France;

Plymouth Univ Peninsula Sch Med Plymouth Devon England;

Toranomon Gen Hosp Dept Med Oncol Tokyo Japan;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Bordeaux Univ Hosp Dept Med Oncol Bordeaux France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (vol 391, pg 748, 2018) [J] . Powles T., Duran I, van der Heijden M. The Lancet . 2018,第10156期

机译：紫红素与化疗在铂治疗的局部晚期或转移性尿路上皮癌（IMVigor211）中：多期，开放标签，第3阶段随机对照试验（Vol 391，PG 748,2018）
2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial (vol 18, pg 672, 2017) [J] . Garcia-Donas J., Font A., Perez-Valderrama B. The lancet oncology . 2019,第1期

机译：Vinflunine的维护疗法加上最佳支持性护理与单独的尿路上皮癌患者的最佳支持性护理（Maja; Sogug 2011/02）：多期，随机，受控，开放标签，第2期试验（Vol 18，PG 672,2017）
3. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial [J] . Garcia-Donas Jesus, Font Albert, Perez-Valderrama Begona, The lancet oncology . 2017,第5期

机译：Vinflunine的维护疗法加上最佳支持性护理与单独的尿路上皮癌患者的最佳支持性护理（Maja; Sogug 2011/02）：多期，随机，受控，开放标签，第2期试验
4. CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma [C] . Zhien Feng, Lizhen Wang, Bingshun Wang, Academic Committee Conference of Shanghai key lab of stomatology . 2011

机译：CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
5. Hypotensive resuscitation versus standard fluid resuscitation for the management of trauma patients in hemorrhagic shock: The safety phase of a randomized controlled trial. [D] . Morrison, C. Anne. 2009

机译：低血压复苏与标准液体复苏在失血性休克中对创伤患者的处理：一项随机对照试验的安全性阶段。
6. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm multicentre phase 2 trial [O] . Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, -1

机译：Atezolizumab作为不适合顺铂治疗的局部晚期和转移性尿路上皮癌患者的一线治疗：一项单臂多中心2期试验
7. Faculty Opinions recommendation of Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. [O] . Matthew Milowsky 2020

机译：atezolizumab在局部晚期和转移性尿路上皮癌患者患者中提出的教师意见，该患者在用铂基化疗进行后进展，单臂，多期，第2期试验。

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅